Table 3.
Multiple linear logistic regression models showing the independent association among demographic and clinical variables and the sleep parameters of PD patients.
| Variable | B coefficients | 95% CI | “p” value |
|---|---|---|---|
| Sleep efficiency | |||
| Constant | 105.17 (13.57) | <0.0001 | |
| Amantadine | −11.37 (6.29) | −24.0 to 1.26 | 0.07 |
| Age, years | −0.57 (0.22) | −1.0 to −0.14 | 0.01 |
|
| |||
| r = 0.41; adjusted r 2 = 0.17 | 0.008 | ||
|
| |||
| Stage 1% | |||
| Constant | 18.49 (2.73) | 13.03 to 23.96 | <0.0001 |
| Dopamine agonist | −9.08 (3.03) | −15.17 to −2.99 | 0.004 |
| Severe H&Y stagea | 15.90 (5.13) | 5.57 to 26.24 | 0.003 |
|
| |||
| r = 0.49; adjusted r 2 = 0.21 | 0.01 | ||
|
| |||
| Stage 2% | |||
| Constant | 67.22 (2.82) | 61.55 to 72.88 | <0.0001 |
| MAO-B inhibitorsb | −16.25 (6.85) | −29.98 to −2.51 | 0.02 |
| MDS-UPDRS IIIc | −11.67 (0.44) | −20.47 to −2.66 | 0.01 |
|
| |||
| r = 0.42; adjusted r 2 = 0.14 | 0.007 | ||
|
| |||
| Stage 3% | |||
| Constant | 10.77 (1.77) | 7.23 to 14.32 | <0.0001 |
| MAO-B inhibitorsb | 8.75 (4.29) | 0.14 to 17.35 | 0.04 |
| MDS-UPDRS IIIc | 4.69 (2.78) | −0.89 to 10.27 | 0.09 |
|
| |||
| r = 0.33; adjusted r 2 = 0.07 | 0.05 | ||
|
| |||
| REM stage % | |||
| Constant | 26.2 (5.73) | 14.69 to 37.68 | <0.0001 |
| Age | −0.21 (0.09) | −0.39 to −0.02 | 0.02 |
|
| |||
| r = 0.30; adjusted r 2 = 0.07 | 0.03 | ||
|
| |||
| Total sleep time, minutes | |||
| Constant | 329.05 (18.26) | 292.42 to 365.69 | <0.0001 |
| Male | 58.59 (28.95) | 0.48 to −116.70 | 0.05 |
| Severe H&Y stagea | −109.58 (61.95) | −233.90 to −14.73 | 0.08 |
|
| |||
| r = 0.35; adjusted r 2 = 0.09 | 0.03 | ||
aH&Y = Hoehn & Yahr stage. Moderate and severe affected patients were grouped as severe H&Y stage; bMAO-B = monoamine oxidase type B; cMDS-UPDRS = Movement Disorders Society-Unified Parkinson's Disease Rating Scale, Part III.